A major Cochrane review of 17 clinical trials involving over 20,000 people has found that anti-amyloid Alzheimer’s drugs do not deliver meaningful clinical benefit.
“The absolute effects of anti-amyloid drugs on cognitive decline and dementia severity were absent or trivial, falling well below established thresholds for the minimum clinically important difference,” the researchers conclude.
Lead author Francesco Nonino, neurologist and epidemiologist at the IRCCS Institute of Neurological Sciences of Bologna, Italy, said: “Unfortunately, the evidence suggests that these drugs make no meaningful difference to patients. There is now a convincing body of evidence converging on the conclusion that there is no clinically meaningful effect. While early trials showed results that were statistically significant, it is important to distinguish between this and clinical relevance.”
These trials have involved substantial global investment over many years from pharmaceutical companies, governments, and charities, reflecting the scale and urgency of the challenge Alzheimer’s presents. Researchers are increasingly recognising that amyloid may be a downstream effect of the disease process rather than its primary cause, suggesting that approaches focused solely on reducing amyloid may be too narrow to deliver meaningful benefit.
David Smith, Emeritus Professor of Pharmacology at the University of Oxford and member of the Scientific Advisory Board of foodforthebrain.org, raises broader concerns: “Anti-amyloid trials also raise important scientific and ethical questions. Is it justifiable to ask patients to undergo yet more trials of anti-amyloid treatments?”
Evidence shows that correcting low levels of B vitamins and omega-3 can produce significant clinical benefit in those with early cognitive decline, without the risks associated with drug interventions. The free, validated Cognitive Function Test, used by over 450,000 people globally, allows individuals to assess their brain health and understand their personal risk factors.
On 28th April, world-leading experts will come together at the Alzheimer’s Prevention: New Frontiers conference, hosted by foodforthebrain.org. The online event will present the latest evidence on drivers of cognitive decline and prevention strategies, covering nutrition, omega-3 and B vitamin status, brain energy and blood sugar balance, sleep, stress, gut health, physical activity, and hormonal changes.
Neurologist Dr. David Perlmutter, a conference speaker, says: “Becoming an Alzheimer’s patient is almost always a choice. This conference will explain why.” foodforthebrain.org is a research and education charity focused on the prevention of Alzheimer’s and supporting mental health.